These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8375126)

  • 1. Effects of renal dysfunction on the pharmacokinetics of loracarbef.
    Therasse DG; Farlow DS; Davidson RL; Quadracci LJ; Hatcher BL; Cerimele BJ; DeSante KA
    Clin Pharmacol Ther; 1993 Sep; 54(3):311-6. PubMed ID: 8375126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isepamicin disposition in subjects with various degrees of renal function.
    Halstenson CE; Kelloway JS; Affrime MB; Lin CC; Teal MA; Shapiro BE; Awni WM
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2382-7. PubMed ID: 1804011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
    Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
    Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceforanide kinetics in renal insufficiency.
    Hawkins SS; Alford RH; Stone WJ; Smyth RD; Pfeffer M
    Clin Pharmacol Ther; 1981 Oct; 30(4):468-74. PubMed ID: 7285481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment.
    Shyu WC; Pittman KA; Wilber RB; Matzke GR; Barbhaiya RH
    J Clin Pharmacol; 1991 Apr; 31(4):362-71. PubMed ID: 2037710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis.
    Sica DA; Marino MR; Hammett JL; Ferreira I; Gehr TW; Ford NF
    Clin Pharmacol Ther; 1997 Dec; 62(6):610-8. PubMed ID: 9433389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
    Blum RA; Kohli RK; Harrison NJ; Schentag JJ
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1470-6. PubMed ID: 2817847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of loracarbef.
    DeSante KA; Zeckel ML
    Am J Med; 1992 Jun; 92(6A):16S-19S. PubMed ID: 1621740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency.
    Kelloway JS; Awni WM; Lin CC; Lim J; Affrime MB; Keane WF; Matzke GR; Halstenson CE
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2267-74. PubMed ID: 1803999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.
    Boike SC; Pue MA; Freed MI; Audet PR; Fairless A; Ilson BE; Zariffa N; Jorkasky DK
    Clin Pharmacol Ther; 1994 Apr; 55(4):418-26. PubMed ID: 8162668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sotalol kinetics in renal insufficiency.
    Blair AD; Burgess ED; Maxwell BM; Cutler RE
    Clin Pharmacol Ther; 1981 Apr; 29(4):457-63. PubMed ID: 7471612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic disposition of loracarbef in healthy young men and women at steady state.
    Sitar DS; Hoban DJ; Aoki FY
    J Clin Pharmacol; 1994 Sep; 34(9):924-9. PubMed ID: 7983236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of sparfloxacin in patients with renal impairment.
    Dorr MB; Johnson RD; Jensen B; Magner D; Marbury T; Talbot GH
    Clin Ther; 1999 Jul; 21(7):1202-15. PubMed ID: 10463518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Famotidine disposition in children and adolescents with chronic renal insufficiency.
    Maples HD; James LP; Stowe CD; Jones DP; Hak EB; Blumer JL; Vogt B; Wilson JT; Kearns GL; Wells TG;
    J Clin Pharmacol; 2003 Jan; 43(1):7-14. PubMed ID: 12520622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of fluconazole in renal failure.
    Berl T; Wilner KD; Gardner M; Hansen RA; Farmer B; Baris BA; Henrich WL
    J Am Soc Nephrol; 1995 Aug; 6(2):242-7. PubMed ID: 7579091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral pharmacokinetics of pirenzepine in patients with chronic renal insufficiency, failure, and maintenance haemodialysis.
    MacGregor T; Matzek K; Keirns J; Vinocur M; Chonko A
    Eur J Clin Pharmacol; 1990; 38(4):405-6. PubMed ID: 2344866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency.
    Humbert G; Leroy A; Fillastre JP; Godin M
    Chemotherapy; 1979; 25(4):189-95. PubMed ID: 456077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
    Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
    J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.